The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 17, 2020

Filed:

Nov. 13, 2017
Applicant:

University of Pittsburgh—of the Commonwealth System of Higher Education, Pittsburgh, PA (US);

Inventors:

Flordeliza Villanueva, Pittsburgh, PA (US);

Andrew Carson, New Castle, PA (US);

Charles F McTiernan, Pittsburgh, PA (US);

Jianjun Wang, Pittsburgh, PA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 9/00 (2006.01); A61K 41/00 (2006.01); A61K 48/00 (2006.01); A61N 7/00 (2006.01); B65D 25/00 (2006.01); C12N 15/113 (2010.01); C12N 15/11 (2006.01); C12N 15/88 (2006.01); C12N 15/87 (2006.01); A61K 9/127 (2006.01);
U.S. Cl.
CPC ...
A61K 9/0002 (2013.01); A61K 9/0009 (2013.01); A61K 41/0028 (2013.01); A61K 48/0075 (2013.01); A61K 48/0083 (2013.01); A61N 7/00 (2013.01); B65D 25/00 (2013.01); C12N 15/111 (2013.01); C12N 15/87 (2013.01); C12N 15/88 (2013.01); A61K 9/127 (2013.01); A61K 9/1272 (2013.01); A61N 2007/0039 (2013.01); C12N 15/1138 (2013.01); C12N 2310/14 (2013.01); C12N 2320/32 (2013.01);
Abstract

The invention pertains to a lipid-based microbubble stably binding a plurality of nucleic acids, and a method of delivering the microbubble and nucleic acids to a specific target site using ultrasound. The delivered nucleic acids create transgenic cells (i.e., for example, a transgenic tumor cell), wherein the transgenic cell expresses the proteins encoded by the delivered nucleic acids. This technology provides a significant improvement for microbubble-drug delivery platforms as known microbubble do not efficiently bind nucleic acids. The improvements described herein include but are not limited to identifying proper lipid proportionality ratios and/or cationic surfactant layers that provide an optimum mechanical index compatible with ultrasonics. Microbubble perfusion and/or nucleic acid delivery may be performed by a combination of imaging and ultrasound/microbubble targeted delivery to simultaneously perform low power two-dimensional imaging and high power microbubble destruction. Such systems are useful in therapeutics and/or diagnositics. For example, the data disclosed herein shows proof of principle in conjunction with the delivery of therapeutic siRNA molecules to slow tumor growth.


Find Patent Forward Citations

Loading…